Technologies personally developed are in 12 active clinical programs (Phase 1–3 + 2 approved products)
Enabled > $2.8 billion in partner/follow-on financing and acquisition value
Platforms transferred to 8 different CDMOs across three continents with zero critical CMC 483s
Mentored 9 scientists who now hold Director/VP roles at flagship gene therapy companies
Licensed patent families have generated > $75 M in upfront + milestone payments to date
These achievements reflect consistent delivery of breakthroughs that move the entire advanced-therapy field forward — from lab innovation to commercial reality.